[MSI-high ascending colon cancer treated with second-line ipilimumab plus nivolumab for conversion surgery:a case report]

Nihon Shokakibyo Gakkai Zasshi. 2023;120(3):256-262. doi: 10.11405/nisshoshi.120.256.
[Article in Japanese]

Abstract

A 68-year-old woman with ascending colon cancer was the patient (cT4bN2M1a [LYM] cStage IVA, BRAF V600E mutation-positive, and MSI-high). She was given modified FOLFOXIRI as first-line therapy but did not respond. The infiltration of the primary lesion in the abdominal wall was alleviated, allowing conversion surgery to be performed.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Colon, Ascending
  • Colonic Neoplasms*
  • Female
  • Humans
  • Ipilimumab
  • Nivolumab*

Substances

  • Nivolumab
  • Ipilimumab